The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Official Title: LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)
Study ID: NCT00466258
Brief Summary: Main objective: * To evaluate the applicability of the treatment: 1. To evaluate the treatment toxicity according to the Common Terminology Criteria (CTC) version 3.0 of the National Cancer Institute (NCI). 2. To evaluate opportunistic and non-opportunistic infections after 6 cycles of treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) administered every 14 days and highly active antiretroviral therapy (HAART) in patients with diffuse large B cell lymphoma (DLBCL) and HIV infection. 3. To evaluate the adherence to the treatment with 6 cycles of R-CHOP considering the delays in the administration of the cycles and the reductions in the doses of chemotherapy (planned dose administered in predicted term). Secondary objectives: * To evaluate the efficacy of the treatment in patients with DLBCL and HIV infection after 6 cycles of treatment with R-CHOP administered every 14 days (R-CHOP/14): 1. To determine the global response and complete remission tax. 2. To evaluate the duration of the response. 3. To evaluate the probability of event-free survival in 5 years. 4. To evaluate the probability of global survival in 5 years. * To identify predictive factors of response after 6 cycles of treatment with R-CHOP administered every 14 days in patients with DLBCL and HIV infection. * To evaluate the impact of the therapeutic combination of R-CHOP and HAART in the parameters of the HIV infection (HIV viral load and CD4+ lymphocyte count).
Detailed Description: This is a clinical trial with a pharmaceutical drug used in the same conditions of authorization.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
H. Son Llatzer, Palma de Mallorca, Baleares, Spain
Germans Trias i Pujol, Badalona, Barcelona, Spain
Consorci Sanitari de Mataró, Mataro, Barcelona, Spain
H. Parc Taulí, Sabadell, Barcelona, Spain
Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain
Hospital de Navarra, Pamplona, Navarra, Spain
H. Clínic i Provincial, Barcelona, Barcelona, , Spain
H. Vall d'Hebron, Barcelona, Barcelona, , Spain
Hospital del Mar, Barcelona, , Spain
Hospital Sant Pau, Barcelona, Barcelona, , Spain
ICO - Duran i Reynals, Hospitalet de Llobregat, Barcelona, , Spain
ICO - Josep Trueta, Girona, , Spain
H. Gregorio Marañón, Madrid, , Spain
H. Joan XXIII, Tarragona, , Spain
Hospital Universitario Dr. Peset, Valencia, , Spain
Name: Ribera Josep M, Dr
Affiliation: Germans Trias i Pujol Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Oriol Albert, Dr
Affiliation: Germans Trias i Pujol Hospital
Role: PRINCIPAL_INVESTIGATOR